Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-27T10:37:08.193Z Has data issue: false hasContentIssue false
  • English
  • Français

Scleroderma and radiotherapy as part of the treatment of breast carcinoma: Six cases and a short critical review of the literature

Published online by Cambridge University Press:  01 March 2007

Youlia M. Kirova ,
Marc A. Bollet ,
Isabelle Dys ,
Francois Campana ,
Fatima Laki ,
Remi Dendale ,
Remy Salmon  and
Alain Fourquet
Youlia M. Kirova
Affiliation:
Department of Radiation Oncology, Institut Curie, Paris, France
Marc A. Bollet
Affiliation:
Department of Radiation Oncology, Institut Curie, Paris, France
Isabelle Dys
Affiliation:
Department of Surgery, Institut Curie, Paris, France
Francois Campana
Affiliation:
Department of Radiation Oncology, Institut Curie, Paris, France
Fatima Laki
Affiliation:
Department of Surgery, Institut Curie, Paris, France
Remi Dendale
Affiliation:
Department of Radiation Oncology, Institut Curie, Paris, France
Remy Salmon
Affiliation:
Department of Surgery, Institut Curie, Paris, France
Alain Fourquet
Affiliation:
Department of Radiation Oncology, Institut Curie, Paris, France
Get access Rights & Permissions [Opens in a new window]

Abstract

Purpose: To add six new cases to the literature and to determine whether women with pre-existing scleroderma have an increased incidence of complications after breast-conserving therapy.

Methods and Materials: From 1995 to 2005, nine patients with pre-existing scleroderma were treated for their breast cancer at the Institute Curie. Six of them underwent radiotherapy. The patients who underwent radiotherapy were irradiated using high-energy photons of a cobalt unit and/or linear accelerator, either before or after surgery, or were exclusively treated using radiation therapy. The early and late skin reactions have been evaluated using the Acute Radiation Morbidity Scoring Criteria (RTOG) and Late Radiation Morbidity Scoring Scheme (RTOG, EORTC).

Results: Median follow-up of the six irradiated patients was 34 months (range from 10 to 120 months). Early reactions were as follows: grade 1 in two cases, grade 2 in two cases, and grade 3 in two cases. Late toxicity was as follows: grade 0 in three patients, currently at 56, 48, and 12 months of follow-up; grade 1, slight atrophy, in two patients; grade 3 reaction with marked atrophy in one patient, followed up for 120 months now. There was no toxicity worse than grade 3 in these series.

Conclusions: This small study cannot provide evidence that scleroderma increases the risk of developing early and late toxicity. Patients with scleroderma must be discussed in multidisciplinary meetings to adapt their treatment to their rheumatologic history. When radiotherapy is considered, more attention must be paid to the protection of normal tissues. Careful follow-up during and after the radiation therapy remains of paramount importance in this specific population of patients.

Keywords

Breast cancersclerodermaradiation therapysurgerytoxicityearly and late side effects
Type
Short Communication
Information
Journal of Radiotherapy in Practice , Volume 6 , Issue 1 , March 2007 , pp. 47 - 51
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;366:2087–2106.CrossRefGoogle Scholar
Toledano, A, Garaud, P, Serin, D, Fourquet, A, Bosset, JF, Breteau, N, Body, G, Azria, D, Le Floch, O, Calais, G. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities: Long-term results of the arcosein multicenter randomized study. Int J Radiat Oncol Biol Phys 2006;65:324–332.CrossRefGoogle Scholar
Vrieling, C, Collette, L, Fourquet, A, Hoogenraad, WJ, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000;55:219–232.CrossRefGoogle ScholarPubMed
Darras-Joly, C, Wechsler, B, Bletry, O, Piette, JC. De novo systemic sclerosis after radiotherapy: a report of 3 cases. J Rheumatol 1999;26:2265–2267.Google ScholarPubMed
Chen, AM, Obedian, E, Hafty, BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 2001;7:475–476.Google ScholarPubMed
Tournillac, I, Dandurand, M, Guillot, B. Bullous lichen sclerosus after radiotherapy. Ann Dermatol Venereol 1998;125:121–123.Google ScholarPubMed
Mayr, NA, Riggs, CE, Saag, KG, Wen, BC, Pennington, EC, Hussey, DH. Mixed Connective Tissue Disease and Radiation Toxicity. Cancer 1998;79:612–618.3.0.CO;2-5>CrossRefGoogle Scholar
Phan, C, Mindrum, M, Silverman, C, Paris, K, Spanos, W. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 2003;9:461–466.CrossRefGoogle ScholarPubMed
Haustain, UF. Exazerbation der progressiven sklerodermie nach röntgentherapie. Hautarzt 1990;41:448–450.Google Scholar
Ross, JG, Hussey, DH, Mayr, NA, Davis, CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 1993;71:3744–3752.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
De Naeyer, B, De Meerleer, G, Braems, S, Vakaet, L, Huys, J. Collagen vascular diseases and radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 1999;44:975–980.CrossRefGoogle ScholarPubMed
Fleck, R, McNeese, MD, Ellerbroek, NA, Hunter, TA, Holmes, FA. Consequences of breast irradiation in patients with pre-existing collagen vascular diseases. Int J Radiat Oncol Biol Phys 1989;17:829–833.CrossRefGoogle ScholarPubMed
Delanian, S, Maulard-Durdux, C, Lefaix, JL, Housset, M. Major interactions between radiation therapy and systemic sclerosis: is there an optimal treatment? Eur J Cancer 1996;32:738–739.CrossRefGoogle Scholar
Wenzel, J. Scleroderma and malignancy: mechanisms of interrelationship. Eur J Dermatol 2002;12:296–300.Google ScholarPubMed
Morris, MM, Powel, SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol 1997;15:2728–2735.CrossRefGoogle ScholarPubMed
Ransom, DT, Cameron, FG. Scleroderma-A possible contra-indication to lumpectomy and radiotherapy in breast carcinoma. Australas Radiol 1987;31:317–318.CrossRefGoogle ScholarPubMed
Cooper, SG, Denham, JW. Progressive systemic sclerosis (diffuse scleroderma) and radiotherapy. Br J Radiol 1990;63:804–805.CrossRefGoogle ScholarPubMed
ICRU Report 50 and ICRU Report 62 (Supplement to ICRU Report 50): Prescribing, recording and reporting photon beam therapy, 1999. Bethesda, Maryland: ICRU.Google Scholar
Fourquet, A, Campana, F, Rosenwald, JC, et al. Breast irradiation in the lateral decubitus position: technique of the Institut Curie. Radiother Oncol 2002;22:261–265.CrossRefGoogle Scholar
Campana, F, Kirova, YM, Rosenwald, JC, et al. Breast radiotherapy in the lateral decubitus position – a technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 2002;61:1348–1354.CrossRefGoogle Scholar
Perez, CA, Brady, LW. Principles and Practice of Radiation Oncology, 2nd edition. Philadelphia: J.B. Lippincott Company 2001; pp 51–55.Google Scholar